Estrella Immunopharma (NASDAQ:ESLA) Share Price Breaks Above 50-Day Moving Average – Time to Sell?

Estrella Immunopharma, Inc. (NASDAQ:ESLA) passed above its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $0.55 and traded as high as $0.7699. Estrella Immunopharma shares last traded at $0.7472, with a volume of 3,907,990 shares.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded Estrella Immunopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, October 28th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Estrella Immunopharma presently has a consensus rating of “Hold” and a consensus price target of $8.00.

Estrella Immunopharma Stock Performance

The firm has a 50 day simple moving average of $0.55 and a 200 day simple moving average of $0.96.

Estrella Immunopharma (NASDAQ:ESLA) last posted its earnings results on Thursday, August 13th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.04. As a group, equities research analysts anticipate that Estrella Immunopharma, Inc. will post -0.25 earnings per share for the current year.

Institutional Investors Weigh In On Estrella Immunopharma

An institutional investor recently bought a new position in Estrella Immunopharma stock. BlackRock Inc. bought a new stake in shares of Estrella Immunopharma, Inc. (NASDAQ:ESLA) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 52,033 shares of the company’s stock, valued at approximately $54,000. BlackRock Inc. owned 0.12% of Estrella Immunopharma as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 0.35% of the company’s stock.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc. (NASDAQ: ESLA) is a clinical-stage biopharmaceutical company focused on developing cellular immunotherapies for cancer and other serious diseases. The company’s work centers on genetically engineered T-cell therapies designed to recognize and destroy target cells. Estrella’s lead program is EB103, a CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy being developed for the treatment of certain B-cell malignancies. The company has described EB103 as being based on its ARTEMIS platform, which is intended to support targeted immune-cell activity while addressing some limitations associated with conventional CAR-T therapies.